glp-1 small molecule agonist BioWorld A small-molecule oral agonist of

Competing interests The authors declare no conflicts of interest

Klusmann, J.-H

doi: 10.7759/CUREUS.66280 58 MeierJJMengeBASchenkerNErdmannSKahle-StephanMSchliessFet al

Together these data indicate that although vagal afferent neurons may contribute to hypophagia induced by peripheral administration of GLP-1R analogs, these neurons are not necessary for the hypophagic effect

Exendin-4 HMSC treatment with GLP-1-RA Exendin-4 (Ex-4), a 39 amino acid peptide originally isolated from Heloderma suspectum venom [14], did not have an influence on GLP-1 receptor nor hMSC surface receptor expression used for cell characterization [14, 15]

49 Further evaluation on a double-blind, randomized phase 1 clinical trial in 98 patients with T2DM on current management with metformin revealed that Danuglipron was generally well tolerated and associated with minimal side effects such as nausea, dyspepsia, and vomiting comparable with the ones observed with the use of injectable GLP-1RA